Loading...

The current price of EVGN is 1.0455 USD — it has decreased -3.15 % in the last trading day.
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Wall Street analysts forecast EVGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVGN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Evogene Ltd revenue for the last quarter amounts to 312.00K USD, decreased -82.07 % YoY.
Evogene Ltd. EPS for the last quarter amounts to 0.44 USD, decreased -133.59 % YoY.
Evogene Ltd (EVGN) has 117 emplpoyees as of December 16 2025.
Today EVGN has the market capitalization of 9.11M USD.